- Home
- TVGN vs NRXP Comparison
TVGN vs NRXP Comparison
Compare TVGN & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVGN | NRXP |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.9M | 54.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TVGN | NRXP |
|---|---|---|
| Price | $4.27 | $2.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 363.6K | ★ 746.7K |
| Earning Date | 05-13-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $9,292.65 |
| Revenue Next Year | N/A | $376.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $1.58 |
| 52 Week High | $10.76 | $3.84 |
Technical Indicators
Market Signals| Indicator | TVGN | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 53.47 | 57.93 |
| Support Level | $0.53 | $1.98 |
| Resistance Level | $10.76 | $2.23 |
| Average True Range (ATR) | 0.75 | 0.17 |
| MACD | -0.26 | 0.06 |
| Stochastic Oscillator | 3.04 | 61.88 |
Price Performance
Historical ComparisonAbout TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.